tetano
Editor, Senior Moderator
PLoS One
. 2022 Jun 24;17(6):e0270141.
doi: 10.1371/journal.pone.0270141. eCollection 2022.
Bicarbonate concentration as a predictor of prognosis in moderately severe COVID-19 patients: A multicenter retrospective study
Ken-Ei Sada[SUP] 1 2 3 [/SUP], Ryohei Yamamoto[SUP] 4 [/SUP], Akihiko Yano[SUP] 3 [/SUP], Atsushi Miyauchi[SUP] 2 [/SUP], Masafumi Kawamura[SUP] 2 [/SUP], Hideki Ito[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) patients reportedly have high bicarbonate concentration. However, its relationship to the disease progression are obscure.
Methods: In this two-center retrospective study, we included COVID-19 patients with moderate severity between March 2020 and May 2021. We classified patients into three groups according to bicarbonate concentrations: high (>27 mEq/L), normal (21 to 27 mEq/L), and low (<21 mEq/L). The primary outcome was the time to clinical worsening defined by the requirement of intubation or death during 90 days. We evaluated high or low bicarbonate concentration during the clinical course related to the primary outcome using multivariable Cox proportional hazard models.
Results: Of the 60 participants (median age 72 years), 60% were men. Participants were classified into high (13 patients), normal (30 patients), and low (17 patients) groups. Clinical worsening occurred in 54% of patients in the high group, 23% in the normal group, and 65% in the low group. Both high and low groups were associated with a higher clinical worsening rate: HR, 3.02 (95% CI, 1.05 to 8.63) in the high group; 3.49 (95% CI: 1.33 to 9.12) in the low group.
Conclusion: Monitoring of bicarbonate concentrations may be useful to predict the prognosis.
. 2022 Jun 24;17(6):e0270141.
doi: 10.1371/journal.pone.0270141. eCollection 2022.
Bicarbonate concentration as a predictor of prognosis in moderately severe COVID-19 patients: A multicenter retrospective study
Ken-Ei Sada[SUP] 1 2 3 [/SUP], Ryohei Yamamoto[SUP] 4 [/SUP], Akihiko Yano[SUP] 3 [/SUP], Atsushi Miyauchi[SUP] 2 [/SUP], Masafumi Kawamura[SUP] 2 [/SUP], Hideki Ito[SUP] 3 [/SUP]
Affiliations
- PMID: 35749694
- DOI: 10.1371/journal.pone.0270141
Abstract
Background: Coronavirus disease 2019 (COVID-19) patients reportedly have high bicarbonate concentration. However, its relationship to the disease progression are obscure.
Methods: In this two-center retrospective study, we included COVID-19 patients with moderate severity between March 2020 and May 2021. We classified patients into three groups according to bicarbonate concentrations: high (>27 mEq/L), normal (21 to 27 mEq/L), and low (<21 mEq/L). The primary outcome was the time to clinical worsening defined by the requirement of intubation or death during 90 days. We evaluated high or low bicarbonate concentration during the clinical course related to the primary outcome using multivariable Cox proportional hazard models.
Results: Of the 60 participants (median age 72 years), 60% were men. Participants were classified into high (13 patients), normal (30 patients), and low (17 patients) groups. Clinical worsening occurred in 54% of patients in the high group, 23% in the normal group, and 65% in the low group. Both high and low groups were associated with a higher clinical worsening rate: HR, 3.02 (95% CI, 1.05 to 8.63) in the high group; 3.49 (95% CI: 1.33 to 9.12) in the low group.
Conclusion: Monitoring of bicarbonate concentrations may be useful to predict the prognosis.